| Pharmaceutical company payments to dermatology clinical practice guideline authors in Japan A Murayama, A Ozaki, H Saito, T Sawano, Y Shimada, K Yamamoto, ... PLoS One 15 (10), e0239610, 2020 | 39 | 2020 |
| Evaluation of conflicts of interest among participants of the Japanese nephrology clinical practice guideline A Murayama, K Yamada, M Yoshida, Y Kaneda, H Saito, T Sawano, ... Clinical Journal of the American Society of Nephrology 17 (6), 819-826, 2022 | 33 | 2022 |
| Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 E Kusumi, A Murayama, S Kamamoto, M Kawashima, M Yoshida, H Saito, ... Blood Cancer Journal 12 (4), 54, 2022 | 31 | 2022 |
| Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan K Yamamoto, A Murayama, A Ozaki, H Saito, T Sawano, T Tanimoto International Urogynecology Journal 32, 443-451, 2021 | 30 | 2021 |
| Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and … A Murayama, K Nakano, S Kamamoto, M Sato, H Saito, T Tanimoto, ... Clinical Microbiology and Infection 28 (12), 1655. e1-1655. e4, 2022 | 27 | 2022 |
| Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis A Murayama, F Kida, A Ozaki, H Saito, T Sawano, T Tanimoto Otolaryngology--head and neck surgery: official journal of American Academy …, 2021 | 27 | 2021 |
| Trend in industry payments to rheumatologists in the United States during the COVID-19 pandemic between 2013 and 2021 A Murayama, S Kamamoto, K Higuchi, H Shigeta, A Ozaki The Journal of Rheumatology 50 (4), 575-577, 2023 | 25 | 2023 |
| Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic A Murayama, S Kamamoto, H Saito, T Tanimoto, A Ozaki Annals of Allergy, Asthma & Immunology 129 (5), 635-636, 2022 | 25 | 2022 |
| Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan T Hashimoto, A Murayama, H Mamada, H Saito, T Tanimoto, A Ozaki Clinical Microbiology and Infection 28 (3), 460-462, 2022 | 25 | 2022 |
| Cross-country student perceptions about online medical education during the COVID-19 pandemic T Suzuki, A Murayama, Y Kotera, D Bhandari, Y Senoo, Y Tani, K Harada, ... International Journal of Environmental Research and Public Health 19 (5), 2840, 2022 | 24 | 2022 |
| Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017 K Harada, A Ozaki, H Saito, T Sawano, K Yamamoto, A Murayama, ... Health Policy 125 (3), 320-326, 2021 | 24 | 2021 |
| A 9-year investigation of healthcare industry payments to pulmonologists in the United States A Murayama, H Kugo, Y Saito, H Saito, T Tanimoto, A Ozaki Annals of the American Thoracic Society 20 (9), 1283-1292, 2023 | 23 | 2023 |
| Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment F Kida, A Murayama, H Saito, A Ozaki, Y Shimada, T Tanimoto Liver International 41 (3), 464-469, 2021 | 23 | 2021 |
| Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines A Murayama, S Kamamoto, N Murata, R Yamasaki, K Yamada, ... Journal of Gastroenterology and Hepatology 38 (4), 565-573, 2023 | 22 | 2023 |
| Japan’s Drug Regulation During the COVID‐19 Pandemic: Lessons From a Case Study of Favipiravir M Ueda, T Tanimoto, A Murayama, A Ozaki, M Kami Clinical Pharmacology and Therapeutics 111 (3), 545, 2022 | 21 | 2022 |
| Nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in Japan between 2016 and 2019 A Murayama, M Hoshi, H Saito, S Kamamoto, M Tanaka, M Kawashima, ... Respiration 101 (12), 1088-1098, 2022 | 20 | 2022 |
| Pharmaceutical payments to Japanese board-certified infectious disease specialists: a four-year retrospective analysis of payments from 92 pharmaceutical companies between 2016 … A Murayama, S Kamamoto, H Saito, K Yamada, D Bhandari, I Shoji, ... International Journal of Environmental Research and Public Health 19 (12), 7417, 2022 | 20 | 2022 |
| Research and nonresearch industry payments to nephrologists in the United States between 2014 and 2021 A Murayama, S Kamamoto, H Kugo, H Saito, A Ozaki Journal of the American Society of Nephrology 34 (10), 1709-1720, 2023 | 19 | 2023 |
| Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal … H Mamada, A Murayama, S Kamamoto, Y Kaneda, M Yoshida, S Sugiura, ... Arthritis Care & Research 75 (6), 1278-1286, 2023 | 19 | 2023 |
| Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the Esophageal Cancer Practice Guidelines 2017 by the Japan Esophageal Society A Murayama, S Kamamoto, H Shigeta, H Saito, E Yamashita, T Tanimoto, ... Diseases of the Esophagus, 2022 | 19 | 2022 |
HIROAKI SAITODepartment of Radiation Health Management, Fukushima Medical UniversityVerified email at fmu.ac.jp
